Purification of Advanced Therapeutics by Flow‐Through Pseudo‐Affinity Chromatography: Bi‐Specific mABs, Fc Fusion Proteins, and Adeno‐Associated Viruses
Biotechnology and Bioengineering · 16.07.2026
DOI: 10.1002/bit.70310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Bioengineering, online erschienen am 16.07.2026. Verfasst von Wenning Chu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, NC State University, Raleigh, North Carolina, USA. Hauptthemen laut MEDLINE: Chromatography, Affinity, Antibodies, Monoclonal, Immunoglobulin Fc Fragments, Dependovirus. Die Arbeit nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute for Innovation in Manufacturing Biopharmaceuticals, FDA HHS, Novo Foundation.
Abstract (Originalsprache)
Modern biopharmaceutical manufacturing requires purification platforms capable of processing structurally and functionally diverse products while addressing the challenge of removing persistent and high‐risk host cell proteins (HCPs). Current purification processes utilize adsorbents that operate in bind‐and‐elute mode, which limits productivity, and often struggle to remove critical impurities. Addressing these limitations, our team developed a flow‐through pseudo‐affinity chromatography platform that utilizes size‐exclusion resins (Monomix Core 500) functionalized with mixed‐mode peptide ligands (AviGuard) to remove process‐related impurities while maximizing productivity and product integrity. This study evaluates this technology across three therapeutic modalities: two bi‐specific monoclonal antibodies (bsAbs) and an Fc‐fusion protein from Chinese hamster ovary (CHO) cell culture fluids, and adeno‐associated virus serotypes 2 and 9 (AAV2 and AAV9) from HEK293 cell lysates. For the CHO‐derived proteins, the platform comprised a pre‐capture step with LigaGuard‐Monomix Core 500 resin (LGMC500), a Protein A‐based capture step, and a polishing step using a single‐use size‐exclusion mixed‐mode (SEMM) resin. This configuration achieved global product yields exceeding 70%, final product pool concentration > 15 mg/mL, monomeric purity ~99%, and excellent cumulative HCP clearance (LRV > 4.5) to residual levels of 60–165 ng/mL (4–11 ppm). For AAV purification, the process utilized a mixed‐bed adsorbent comprising dextran‐coated charcoal and LGMC500 for removing HCPs, cell metabolites, and media components, followed by a capture step using either CaptureSelect AAVX resin or Natrix CH membranes. The optimization of the charcoal‐to‐resin volume ratio (1:3) and load volume (~ 10 14 vp per mL of resin) yielded ~50% AAV recovery with a residual HCP level of 350 ng/mL, representing < 100 ng per dose, in compliance with regulatory guidelines. Process productivity ranged from 19 to 23 g/L·hr for CHO‐derived proteins and ~7 × 10 14 vp/L·hr for AAV9, positioning this technology in the optimal operating space for modern bioprocessing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Biomolecular Engineering, NC State University, Raleigh, North Carolina, USA.
- North Carolina Viral Vector Initiative in Research and Learning (NC-VVIRAL), NC State University, Raleigh, North Carolina, USA.
- Biomanufacturing Training and Education Center (BTEC), NC State University, Raleigh, North Carolina.
- Molecular Education, Technology, and Research Innovation Center (METRIC), NC State university, Raleigh, North Carolina, USA.
- Analytical Research & Development, Merck & Co., Rahway, New Jersey, USA.
- Process Research and Development, Merck & Co., Rahway, New Jersey, USA.
ORCID-Profile: Wenning Chu, Arianna Minzoni, Xuanwen Li, Divya Chandra, Steven Cramer, Abraham Lenhoff, Stefano Menegatti
Förderung
- National Institute for Innovation in Manufacturing Biopharmaceuticals
- FDA HHS
- Novo Foundation
- North Carolina Viral Vector Initiative in Research and Learning (NC-VVIRAL)
- U.S. Food and Drug Administration
Zitieren
APA
Chu, W., Barbieri, E., Minzoni, A., Shastry, S., LeBarre, J. P., Shu, Q., Williams, T., Li, X., Chandra, D., Xu, X., Bill, J., Roush, D., Taris, J., Gilbert, P., Kiesewetter, A., Rammo, O., Schulte, M., Major, C., Mouchahoir, T., …, & Menegatti, S. (2026). Purification of Advanced Therapeutics by Flow‐Through Pseudo‐Affinity Chromatography: Bi‐Specific mABs, Fc Fusion Proteins, and Adeno‐Associated Viruses. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70310
Vancouver
Chu W, Barbieri E, Minzoni A, Shastry S, LeBarre JP, Shu Q, et al. Purification of Advanced Therapeutics by Flow‐Through Pseudo‐Affinity Chromatography: Bi‐Specific mABs, Fc Fusion Proteins, and Adeno‐Associated Viruses. Biotechnology and Bioengineering. 2026. doi:10.1002/bit.70310
BibTeX
@article{Chu2026,
author = {Chu, Wenning and Barbieri, Eduardo and Minzoni, Arianna and Shastry, Shriarjun and LeBarre, Jacob P and Shu, Qingbo and Williams, Taufika and Li, Xuanwen and Chandra, Divya and Xu, Xuankuo and Bill, Jerome and Roush, David and Taris, Joseph and Gilbert, Patrick and Kiesewetter, Andre and Rammo, Oliver and Schulte, Michael and Major, Christopher and Mouchahoir, Trina and Cramer, Steven and Boi, Cristiana and Carbonell, Ruben G and Lenhoff, Abraham and Menegatti, Stefano},
title = {Purification of Advanced Therapeutics by Flow‐Through Pseudo‐Affinity Chromatography: Bi‐Specific mABs, Fc Fusion Proteins, and Adeno‐Associated Viruses},
journal = {Biotechnology and Bioengineering},
year = {2026},
doi = {10.1002/bit.70310}
}
EUVIMED